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General introduction 
 
Intravenous immunoglobulin (IVIg) therapy is the injection therapy of pooled 
human immunoglobulin derived from thousands of blood donation volunteers.  The 
major component of IVIg agent is polyclonal immunoglobulin G (IgG) fraction 
prepared from human plasma [1], and a large amount of immunoglobulins (0.1-2 g/kg 
body mass) is administered to patients with autoimmune and severe infectious diseases 
[2].   
The IVIg therapy has a long history.  In 1890, von Behring firstly communicated 
serum application against diphtheria [3] and tetanus [4].  Since then, IVIg has been 
object of intense investigation in terms of function and clinical application [1].  Later, 
IVIg was tried to use for patients with primary antibody defiencies who developed 
chronic bacterial infections [5], and the first application of IVIg for autoimmune 
diseases was proposed in 1981 [6].  Nowadays, the therapeutic efficacy of IVIg is 
widely accepted.  Indeed, the IVIg therapy adapts serious inflammatory diseases such 
as Kawasaki disease (KD), Guillain-Barre symdrome, idiopathic thrombocytopenic 
purpura (ITP), systemic lupus erythematosus (SLE), and chronic inflammatory 
demyelinating polyneuropathy (CIDP). 
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Autoimmune diseases are conditions elicited by abnormal immune responses to a 
normal body part, and many of them are accompanied by acute or chronic inflammation.  
Several autoimmune diseases are designated as intractable diseases in Japan, and their 
accurate mechanisms for pathogenesis and effective treatment are not completely 
established.  Contemporary theories suggest that autoimmunity is the result of a 
multi-orchestrated immune response, and the overview of autoimmune progression is 
described in Fig. 1 [7].  The recognition of molecular mimicry, xenobiotics and 
autoantigen by antigen presenting cells (APC) including dendritic cells (DC), 
macrophages (M), and natural killer cells (NK) lead to initiation of autoimmunity (Fig. 
1A).  The activated APC present antigenic peptides to uncommitted T helper (Th0) 
lymphocytes, which then differentiate into Th2, follicular helper (Tfh), Th17, Th1 or 
regulatory T cells (Treg) (Fig. 1B).  B cells are activated by Tfh and Th2, and then 
become mature and differentiate into plasma cells, which produce autoantibodies (Fig. 
1C).  Through antibody-dependent cell-mediated cytotoxicity (ADCC), interaction 
with receptor of target cells and deposition of immune complex (IC), and autoantibodies 
may mediate autoimmune diseases (Fig. 1D).  These autoimmune mechanisms via 
autoantibodies are observed in SLE [8], Sjogren’s syndrome (SS) [9], and rheumatoid 
arthritis (RA) [10].  Increased Th17 provokes inflammation through secretion of 
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interleukin (IL)-17 in several autoimmune diseases such as RA [11], SLE [12], SS [13], 
and multiple sclerosis (MS) [14] (Fig. 1E).  Th1 cells drive the development of 
cytotoxic T lymphocytes (CTL), which cause tissue injury by secretion of cytotoxic 
granules or cytokines (Fig. 1F).  Cytotoxicity driven by Th1 is seen in type 1 diabetes 
(T1D) [15] and primary biliary cirrhosis (PBC) [16].  Decreased Treg, which 
negatively regulates both innate and adaptive immune responses, disturbs immune 
tolerance (Fig. 1G).  Low level of Treg occurs in SLE [17], MS [18], and RA [19].   
Treatment by using steroids or immunosuppressant is the major approach to treat 
autoimmune diseases as a symptomatic treatment.  However, these treatments are not 
suitable for patients lacking physical strength such as children and after surgery, 
because normal immune responses are also impeded by steroids or immunosuppressant.  
IVIg is the alternative therapy for above cases, and moreover, it is vital for patients in 
acute phase of severe inflammation as a last-minute strategy.  For example, IVIg is a 
representative therapy of KD, which is an acute self-limited vasculitis of unknown 
etiology that occurs predominantly in infants and young children [20].  The 
recommended therapy for all KD patients in the acute phase generally administers IVIg 
agent, 2 g/kg over 10-12 hours [21].  In the case of SLE, which is a multisystem 
autoimmune disease with diverse manifestation, some reports suggest that IVIg may be 
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beneficial and safe for various manifestations in mice model as well as in human 
patients [22,23] .  Thus, the anti-inflammatory effects of IVIg are widely recognized in 
mouse models of inflammatory disorders and human clinical settings.  However, the 
accurate mechanisms of IVIg remain to be elucidated.   
To elucidate therapeutic mechanisms of IVIg is quite important in order to 
develop more effective and safer treatment techniques.  Not only benefits, but IVIg 
therapy gives physical burden by high dose of immunoglobulin agent and long-time 
injection.  In addition, it is a disadvantage that the risk of infection cannot be 
completely ruled out because IVIg agent derives from pooled human plasma.  To solve 
these problems, it is necessary to develop molecular targeted drugs that mimic the 
therapeutic effects of IVIg.  However, the creation of molecular targeted drugs is 
difficult under the current situation in which the therapeutic mechanisms of IVIg are not 
clear.  Therefore, basic research to understand the therapeutic mechanisms of IVIg 
would play a part in the development of therapeutic techniques for the treatment of 
inflammatory diseases.   
In this thesis, I aimed to redefine and elucidate the target cell subsets and 
immunosuppressive mechanisms of IVIg based on a hypothesis that IVIg fulfills its 
immunosuppressive activities through multiple cell targets and molecular mechanisms.  
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B cells and T cells play critical roles in the advance of inflammation (Fig. 1).  Thus, I 
focused on the immunosuppressive effects of IVIg on B cells and T cells.  In chapter 1, 
I tried to reveal immunosuppressive role of IVIg on steady-satate B cells.  In chapter 2, 
I attempted to elucidate immunosuppressive effect of IVIg on activated T cells.  The 
present results would provide new insight into exploration of valuable drug targets on 
the treatment of chronic and acute inflammatory disorders. 
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Fig. 1 Autoimmunity is a result of a multi-orchestrated immune response [7, 
modified].  A The recognition of molecular mimicry, xenobiotics and autoantigen by 
APC such as DC, M, and NK lead to initiation of autoimmunity.  B The activated 
APC present antigenic peptides to Th0 lymphocytes, which then differentiate into Th2, 
Tfh, Th17, Th1 or Treg.  C B cells are activated by Tfh and Th2, and then become 
mature and differentiate into plasma cells.  D Through antibody-dependent 
cell-mediated cytotoxicity (ADCC), interaction with receptor of target cells and 
deposition of immune complex (IC), and autoantibodies can mediate autoimmune 
diseases. 
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Chapter 1: Intravenous immunoglobulin (IVIg) acts directly on 
steady-state B cells to suppress their homeostatic 
expansion 
 
1.1. Introduction 
 
     B cells are a type of lymphocytes, and their role in immune system is secreting 
antibodies to eliminate pathogenetic antigens such as virus and bacteria.  However, B 
cells also play a critical role in the pathogenic inflammatory response by producing 
autoantibodies in autoimmune disorders [7].  For example, the level of anti-nuclear 
antibodies to double-stranded DNA, Sjogren’s syndrome (SS)-A and SS-B in plasma 
are diagnostic criteria for systemic lupus erythematosus (SLE) and SS [8,9].  IVIg has 
been evaluated for its therapeutic effects in above-mentioned autoimmune diseases 
characterized by over production of autoantibodies. 
     Previous studies have proposed several inhibitory activities of IVIg on B cells.  
IVIg suppresses B cell activation through agonistic binding to inhibitory receptors 
CD22 [24,25] and FcRIIB [26] on B cells.  IVIg also interacts with B cell receptor 
(BCR) [27,28] or toll-like receptors (TLR) [29,30] to negatively regulate B cell 
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activation.  Although those B cell immunosuppressive activities of IVIg acts on 
activated B cells, the impact of IVIg on steady-state B cells still remains to be 
elucidated. 
     Dysregulation of immune homeostasis can lead to induction of autoimmune 
diseases [31].  Especially, failure of B cell homeostasis in steady-state mediates 
autoimmune disorders, and hyper-activation of B cells is involved in the deterioration of 
chronic inflammation [32,33].  Thus, keeping B cells in normal homeostasis is 
important to prevent chronic inflammation leading to autoimmune diseases, and to test 
whether IVIg affects B cell homeostatic expansion is intriguing trial for elucidation of B 
cell inhibitory activity of IVIg. 
     In this chapter, I show that IVIg acts directly on steady-state B cells, and 
suppresses their homeostatic expansion accompanied with B cell-specific cell 
aggregation.  Present results provide new insight into the B cell regulatory activities of 
IVIg. 
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1.2. Materials and methods 
 
1.2.1. Mice and ethical statement 
Five-week-old female BALB/c mice were purchased from Charles River 
Laboratories Japan (Kanagawa, Japan) and kept under specific pathogen-free conditions 
until use.  All animal experiments were followed the protocols approved by the 
Committee on Animal Experimentation of Hiroshima University, Japan. 
 
1.2.2. Reagents 
Pooled human immunoglobulin agent (Sanglopor® I.V. Infusion) and human 
albumin were purchased from CSL Behring and FUJIFILM Wako Pure Chemical 
Corporation (Osaka, Japan) respectively.  Purchased agent and albumin were 
reconstituted with endotoxin-free saline (Otsuka Pharmaceutical Factory, Tokushima, 
Japan) as 200 mg/ml aliquots and kept at -20˚C until use.  All chemicals were 
biochemical grade or cell culture grade. 
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1.2.3. Purification or depletion of B and T cells from murine splenocytes  
CD19-positive (CD19+) B cells or CD3-positive (CD3+) T cells were purified 
from splenocytes of BALB/c mice by using anti-CD19 antibody-conjugated magnetic 
beads or Pan T cell Isolation Kit II (Miltenyi Biotec, Bergisch-Gladbach, Germany) 
following the manufacturer’s instruction.  For depletion of CD19+ B cells or CD3+ T 
cells, splenocytes were also treated anti-CD19 antibody-conjugated magnetic beads or 
Pan T cell Isolation Kit II following the manufacturer’s instruction. 
 
 
1.2.4. Cell labeling with fluorescent dye 
3×106 purified CD19+ B cells were stained with 400-fold-diluted Orange 
Fluorescent Cytoplasmic Membrane Staining Kit (Takara Bio, Shiga, Japan) for 2 min.  
5×106 purified CD3+ T cells were stained with 1 M 5-(and 6)-carboxyfluorescein 
diacetate succinimidyl ester (CFSE; Affymetrix Japan, Tokyo, Japan) for 10 min.  
Labeled B cells, T cells and non-labeled non-B/T cells were reconstituted for original 
subset rate of splenocytes. 
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1.2.5. Cell culture 
For proliferation assay, 3×105 whole splenocytes, B or T cell-depleted 
splenocytes, and purified B or T cells were cultured with 10 mg/ml IVIg or human 
albumin, 50 g/ml mitomycin C, or saline as a vehicle control in 200 l of RPMI 
medium (Sigma-Aldrich, St. Louis, MO, USA), containing 10% fetal bovine serum 
(FBS; Sigma-Aldrich), 50 M 2-mercaptoethanol (Nacalai Tesque, Kyoto, Japan), 100 
units/ml penicillin (Thermo Fisher Scientific, Waltham, MA, USA) and 100 g/ml 
streptomycin (Thermo Fisher Scientific), for 48 h in 96-well flat-bottom culture plates 
(Corning, Corning, NY, USA). 
For microscopic analysis, 3×105 naive splenocytes, B or T cell-depleted splenocytes, 
purified B or T cells, or B and T cell-labeled splenocytes were cultured with 10 mg/ml 
IVIg or human albumin, 50 g/ml mitomycin C, or saline in 200 l of RPMI medium 
for 48 h in triple-well glass-base dish (Asahi Glass, Tokyo). 
 
1.2.6. Proliferation assay 
Cell proliferation was estimated by BrdU incorporation during the last 18 h of 
48-hour cultivation.  BrdU incorporation was determined by Cell Proliferation 
Enzyme-linked Immunosorbent Assay (ELISA) BrdU (colorimetric) Kit (Roche 
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Diagnostics, Mannheim, Germany) following the manufacturer’s instruction. 
 
1.2.7. Microscopic analysis 
Fluorescent dye-labeled splenocytes were detected by fluorescence microscopy 
(BZ-9000, Keyence, Osaka, Japan) after 48 h cultivation. 
 
1.2.8. Neutralization of Fc receptors (CD16/32) and integrin 2 (CD18) 
Naive splenocytes were incubated with 16 g/ml anti-CD16/32 antibody 
(eBioscienceTM, Thermo Fisher Scientific), 16 g/ml rat IgG2a isotype control antibody 
(eBioscienceTM, Thermo Fisher Scientific), 20 g/ml anti-CD18 antibody (BioLegend, 
San Diego, CA, USA), or 20 g/ml rat IgG2a isotype control antibody (BioLegend) for 
15 min at 4˚C.  Then, 20 mg/ml IVIg or albumin, 100 g/ml mitomycin C or saline 
was added, and splenocytes were cultured for 48 h.  The final concentration of each 
reagent was 8 g/ml anti-CD16/32 antibody or their isotype control antibody, 10 g/ml 
anti-CD18 antibody or their isotype control antibody, 10 mg/ml IVIg and albumin, and 
50 g/ml mitomycin C. 
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1.2.9. Statistical analysis 
Data are represented as mean ± SD.  Representative data are from three 
independent experiments.  A non-repeated analysis of variance (ANOVA) was applied 
to the comparisons of data among four groups; when a difference was significant, a post 
hoc analysis using the Turkey’s test was performed.  Statistical significance was 
defined as p < 0.05. 
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1.3. Results 
 
1.3.1. IVIg suppresses proliferation of murine splenocytes in steady-state 
To test the immunosuppressive capacity of IVIg, I first cultured naive murine 
splenocytes with IVIg and assessed its anti-proliferative effect.  IVIg suppressed 
proliferation of unstimulated splenocytes as compared with these stimulated with 
human albumin and saline (Fig. 2A).  In addition, I also found that IVIg induced of 
cell aggregation (shown as arrows in Fig. 2B).  These results show that IVIg fulfills 
two effects on steady-state immune cells; IVIg suppressed homeostatic proliferation of 
splenocytes accompanied with cell aggregation. 
 
1.3.2. IVIg suppresses homeostatic proliferation of B cells 
To explore the responsible cell types of IVIg-derived immunosuppressive activity 
in steady-state, I depleted or isolated major immune cells, B cell and T cells, from 
whole splenocytes, and tested the immunosuppressive activity of IVIg on these 
fractionated cell subsets.  IVIg significantly suppressed homeostatic proliferation of 
whole splenocytes (“Whole splenocytes” in Fig. 3).  However, B cell-depletion from 
splenocytes abolished homeostatic proliferation seen on whole splenocytes (“B 
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cell-depleted” in Fig. 3).  In contrast, T cell-depletion from splenocytes was not 
affected on induction of homeostatic proliferation, and IVIg suppressed the homeostatic 
expansion of T cell-depleted splenocytes (“T cell-depleted” in Fig. 3).  Furthermore, 
IVIg significantly suppressed homeostatic proliferation of purified B cells (“Purified B 
cells” in Fig. 3), and purified T cells did not possess homeostatic proliferation (“Purified 
T cells” in Fig. 3).  These in vitro data suggest that steady-state B cells show the 
activity of homeostatic expansion, and IVIg suppresses their homeostatic proliferation. 
 
1.3.3. IVIg induces B cell-specific aggregation 
The B cell immunosuppression by IVIg treatment was accompanied by cell 
aggregation (Fig. 2B).  To investigate the responsible cell population of IVIg-mediated 
cell aggregation, I also depleted or isolated B cells and T cells from splenocytes.  IVIg 
induced cell aggregation in whole splenocytes culture (“Whole splenocytes” in Fig. 4A).  
T cell-depletion from splenocytes had no effect on IVIg-driven cell aggregation seen on 
whole splenocytes (“T cell-depleted” in Fig. 4A), but B cell-depletion from splenocytes 
abolished induction of cell aggregation (“B cell-depleted” in Fig. 4A).  Moreover, IVIg 
induced cell aggregation on purified B cells (“Purified B cells” in Fig. 4A), and purified 
T cells failed to form cell aggregation upon stimulation with IVIg (“Purified T cells” in 
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Fig. 4A).  Then, I stained B cells and T cells with fluorescent dyes to confirm whether 
the IVIg-triggered cell aggregation consisted of only B cells.  IVIg induced 
aggregation of orange dye-labeled B cells, but not green dye-labeled T cells (“IVIg” in 
Fig. 4B).  These data suggest that B cells are essential for IVIg-driven cell aggregation, 
and the cell aggregates mainly composed of B cells. 
 
1.3.4. Fc receptors and integrin 2 are not involved in IVIg-mediated aggregation and 
suppression of homeostatic proliferation 
Above results suggest that IVIg directly acts on steady-state B cells to suppress 
their homeostatic expansion.  Previous study reported that IVIg induced CD32 (a 
low-affinity Fc receptor; FcRII) -mediated platelet aggregation [34].  CD32 is also 
expressed on the surface of B cells.  Furthermore, Fc receptors are proposed as the 
key target molecules of immunosuppressive function of IVIg [35,36].  To analyze 
involvement of Fc receptors in IVIg-drived B cell aggregation, I tested whether 
neutralizing antibody against Fc receptors (CD16 and CD32) canceled induction of B 
cell aggregation.  Treatment with anti-CD16/CD32 antibody was not affected on 
induction of B cell aggregation, shown as orange clusters (Fig. 5A).  In addition, B 
cells express adhesion molecule CD18 (integrin 2), which is important molecule for B 
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cell aggregation [37].  I also tested the involvement of CD18 in IVIg-derived B cell 
aggregation by using neutralizing antibody against CD18.  B cell aggregation, shown 
as orange cluster, was still intact even when co-cultured with anti-CD18 antibody (Fig. 
5B).  These data indicate that Fc receptors and integrin 2 are unnecessary for B cell 
aggregation induced by IVIg. 
To confirm whether Fc receptors and integrin 2 were needed for inhibition of B 
cell homeostatic proliferation by IVIg treatment, I also assessed immunosuppressive 
activity of IVIg upon co-culture with neutralizing antibody against CD16/CD32 or 
CD18.  IVIg significantly suppressed homeostatic proliferation of splenocytes 
co-cultured with anti-CD16/CD32 as well as with anti-CD18 (Fig. 6).  These results 
suggest that Fc receptors and CD18 are also dispensable for suppression of B cell 
homeostatic proliferation by IVIg treatment. 
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1.4. Discussion 
 
     In this chapter, I revealed that IVIg acted directly on steady-state B cells and 
suppressed their homeostatic proliferation. The B cell inhibitory activity was 
accompanied with B cell aggregation, and adhesion molecule (integrin 2/CD18) and 
FcRs (CD16/32) on B cells were dispensable for IVIg-driven B cell regulation.  These 
results provide a new insight into immunosuppressive capacity of IVIg on dysregulation 
of B cell homeostasis leading to abnormal B cell activation.  
     An intriguing point on the homeostatic expansion of B cells is that the other 
lymphocytes do not possess such homeostatic proliferation like B cells.  Indeed, B 
cell-depletion from splenocytes abolished homeostatic proliferation seen on whole 
splenocytes (“B cell-depleted” in Fig. 3), and purified T cells did not growth in 
steady-state (“Purified T cells” in Fig. 3).  These findings suggest that B cell-specific 
growth factors regulate B cell homeostatic proliferation, and IVIg suppresses their 
activity triggered by those growth factors.  B cell activating factor (BAFF) is known as 
a modulator of B cell homeostasis [38].  The serum level of BAFF is elevated in 
patients with SLE and positively correlates with disease activity [39,40].  Besides, the 
level of BAFF correlates with the titer of autoantibodies in SS [41].  A plausible 
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inhibitory mechanism of IVIg would be that IVIg suppresses BAFF-mediated B cell 
homeostatic proliferation through inhibition of BAFF reseptor (BAFFR, TNF-receptor 
super-family) signaling.  B cells express BAFFR on its cell surface and the receptor 
triggers the non-canonical NF-B-dependent pathway [42,43].  In addition, binding of 
BAFF to BAFFR activates the phosphoinositide-3-kinase (PI3K)-dependent signaling 
cascade [44].  To test whether IVIg acts on BAFF receptor and suppresses these 
signaling pathways would be intriguing future issue.  Furthermore, previous reports 
suggest that activation of B cells is contributed by sex hormones [45], which play 
essential roles in sexual development of female.  Actually, SLE characterized by the 
production of multiple autoantibodies is higher prevalence in women than men [46].  
For concrete example, it has been demonstrated that treatment of women with estrogen 
(one of the sex hormone) or exposure of human peripheral blood mononuclear cells 
(PBMC) to estrogen lead to higher levels of immunoglobulins [47].  Another sex 
hormone, prolactin, enhances secretion of BAFF and immunoglobulins [48].  Prolactin 
is produced by B cells, and B cells also express prolactin receptors [49].  Thus, these 
sex hormones would be the responsible growth factor for homeostatic expansion of B 
cells.  Most of estrogen’s effects are mediated two specific intracellular receptors, 
estrogen receptor (ER)  and , which function as ligand- activated nuclear 
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transcription factors producing genomic effects [50].  The JAK/STAT pathway is the 
main signaling pathway used by prolactin receptors [51,52].  To assess participation of 
these molecules and pathways to homeostatic expansion of B cells would provide 
insights into identification of the B cell regulatory mechanism by IVIg. 
     Another unsolved issue is identification of target molecule to suppress B cell 
homeostatic proliferation and to form B cell aggregation by IVIg.  In this thesis, I 
showed that neutralization of plausible molecules (integrin 2 and FcRs) failed to 
abrogate anti-proliferative activity and formation of aggregation by IVIg (Fig. 5 and 6).  
In a preliminary trial based on the hypothesis that IVIg acted on a B cell surface target 
molecule and fulfilled its inhibitory activity, I found that immunoprecipitates of B cell 
lysate by IVIg contained myosin-9 (data not shown).  This molecule is involved in 
infection of Epstein-Barr virus (EBV) on nasopharyngeal epithelial cell membrane [53].  
EBV also infects B cells to cause lymphomas [53].  Myosin-9 would be a candidate of 
the target of IVIg, and further analysis is required for decision of responsible antigen 
that binds to IVIg. 
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Fig. 2 IVIg suppresses proliferation of murine splenocytes in steady-state.  A IVIg 
suppressed homeostatic proliferation of murine splenocytes.  Unstimulated murine 
splenocytes were cultured with IVIg (10 mg/ml), albumin (10 mg/ml) or saline for 48h.  
Proliferation was estimated by BrdU incorporation.  *Significantly different at p < 
0.05 among saline, albumin, and IVIg by non-repeated ANOVA and the post hoc Tukey 
test.  Data are presented as means ± SD (n = 3).  B IVIg induced cell aggregation.  
Each image is shown cultured splenocytes with IVIg (10 mg/ml), albumin (10 mg/ml) 
or saline for 48 h, respectively.  All scale bars represent 100 m. 
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Fig. 3 IVIg suppresses homeostatic proliferation of B cells.  Whole splenocytes, B 
cell-depleted splenocytes, T cell-depleted splenocytes, purified B cells or purified T 
cells were cultured with IVIg (10 mg/ml), albumin (10 mg/ml), mitomycin C (50 g/ml) 
or saline.  The proliferation was measured by BrdU incorporation.  *Significantly 
different at p < 0.05 among saline, albumin, IVIg, and mitomycin C by non-repeated 
ANOVA and the post hoc Tukey test.  Data are presented as means ± SD (n = 3). 
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Fig. 4 IVIg induces B cell-specific aggregation.  A IVIg induced B cell aggregation.  
Whole splenocytes, T cell-depleted splenocytes, B cell-depleted splenocytes, purified B 
cells or purified T cells were cultured with IVIg (10 mg/ml) for 48 h.  All scale bars 
represent 100 m.  B IVIg induced B cell aggregation in reconstituted splenocytes.  B 
cells or T cells were stained with orange or green fluorescent dye, respectively.  
Orange dye-labeled B cells, green dye-labeled T cells and unstained non-B/T cells were 
reconstituted to consist of B and T cell-labeled splenocytes.  Reconstituted splenocytes 
were cultured with IVIg (10 mg/ml), albumin (10 mg/ml) or saline for 48 h and 
analyzed by a fluorescence microscopy.  All scale bars represent 100 m. 
24 
 
 
 
 
Fig. 5 Fc receptors and integrin 2 are not involved in IVIg-mediated cell 
aggregation.  A CD16 and CD32 were dispensable for IVIg-drived cell aggregation.  
Splenocytes pre-incubated with anti-CD16/CD32 or isotype IgG2a antibody were 
cultured with IVIg (10 mg/ml) for 48 h and analyzed by a fluorescence microscopy.  
All scale bars represent 100 m.  B CD18 was dispensable for IVIg-derived cell 
aggregation.  Splenocytes pre-incubated with anti-CD18 or isotype IgG2a antibody 
were cultured with IVIg (10 mg/ml) for 48 h and analyzed by a fluorescence 
microscopy.  All scale bars represent 100 m. 
  
25 
 
 
 
Fig. 6 Fc receptors and integrin 2 are not involved in IVIg-driven suppression of 
homeostatic proliferation.  Fc receptors and integrin 2 were unnecessary for 
IVIg-drived suppression of homeostatic proliferation.  Splenocytes pre-incubated with 
anti-CD16/CD32, anti-CD18 or isotype IgG2a antibody were cultured with IVIg (10 
mg/ml), albumin (10 mg/ml), mitomycin C (50 g/ml) or saline.  The proliferation was 
measured by BrdU incorporation.  *Significantly different at p < 0.05 among saline, 
albumin, IVIg, and mitomycin C by non-repeated ANOVA and the post hoc Tukey test.  
Data are presented as means ± SD (n = 3). 
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Chapter 2: IVIg acts directly on conventional T cells to suppress their 
activation upon T cell receptor (TCR) ligation 
 
2.1. Introduction 
 
     In the previous chapter, I found that IVIg acts directly on steady-state B cells, and 
suppresses their homeostatic proliferation accompanied with B cell aggregation.  
However, not only B cells but also T cells cause autoimmune diseases.  In fact, T 
cell-driven pathogenesis is observed in several autoimmune disorders.  For example, 
high level of IL-17 produced by Th17 cells progresses inflammation in patients of 
rheumatoid arthritis (RA) [11] and multiple sclerosis (MS) [14], and cytotoxic T cells 
provoke type 1 diabetes (T1D) [15] and primary biliary cirrhosis (PBC) [16].  Besides, 
decreased Treg which negatively regulates immune responses leads to deficiency of 
immune tolerance in patients with SLE, MS, and RA [17,18,19].  IVIg has therapeutic 
effects on those T cell-triggered autoimmune diseases. 
     Recent works have proposed T cell regulatory mechanisms of IVIg, but most of 
them suggest that IVIg expands Treg to suppress T cell activation.  IVIg induces Treg 
expansion through the antigen presentation of IgG Treg epitopes (Tregitopes, IVIg 
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Fc-derived antigen peptides) [54].  IL-33 [55] or prostaglandin E2 [56] produced by 
IVIg-treated antigen presenting cells (APC) also expands Treg.  Therefore, all of those 
T cell immunosuppressive actions of IVIg are indirectly fulfilled via APC and Treg, but 
the direct impact of IVIg on T cells remains to be elucidated. 
     In this chapter, I show that IVIg acts directly on conventional T cells and 
suppresses their activation upon TCR ligation.  Present results provide new 
mechanistic insight into the T cell regulatory activity of IVIg. 
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2.2. Materials and methods 
 
2.2.1. Mice and ethical statement 
Five-week-old female BALB/c mice were purchased from Charles River 
Laboratories Japan (Kanagawa, Japan) and kept under specific pathogen-free conditions 
until use.  All animal experiments were followed the protocols approved by the 
Committee on Animal Experimentation of Hiroshima University, Japan. 
 
2.2.2. Reagents 
Pooled human immunoglobulin agent (Sanglopor® I.V. Infusion) and human 
albumin was purchased from CSL Behring and FUJIFILM Wako Pure Chemical 
Corporation (Osaka, Japan) respectively.  Purchased agent and albumin were 
reconstituted with endotoxin-free saline (Otsuka Pharmaceutical Factory) as 200 mg/ml 
aliquots and kept at -20˚C until use.  Phytohemagglutinin (PHA), concanavalin A (Con 
A) and lipopolysaccharide (LPS) were purchased from Sigma-Aldrich.  PHA and LPS 
were reconstituted with phosphate buffered saline (PBS; FUJIFILM Wako Pure 
Chemical Corporation) as 1 mg/ml aliquots, and Con A was reconstituted with dimethyl 
sulfoxide (DMSO; Sigma-Aldrich) as 5 mg/ml aliquots.  All stimulants aliquots kept at 
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-20˚C until use.  All of the chemicals used were of biochemical grade or cell culture 
grade. 
 
2.2.3. Cultivation of splenocytes with immunostimulants 
3×105 splenocytes prepared from female BALB/c mice were cultured with 1.25, 
2.5, 5, 10, or 20 μg/ml PHA, 0.125, 0.25, 0.5, or 1 g/ml Con A, 0.125, 0.25 0.5, 1, 2, or 
4 µg/ml LPS, or 0.125, 0.25 0.5, 1 g/ml immobilized anti-CD3 antibody upon 
co-stimulation with 10 mg/ml IVIg or human albumin in 200 µl of culture medium.  
The culture medium based on RPMI medium (Sigma-Aldrich), and supplemented 10% 
fetal bovine serum (FBS; Sigma-Aldrich), 50 µM 2-mercaptoethanol (Nacalai Tesque) 
100 units/ml penicillin (Thermo Fisher Scientific) and 100 µg/ml streptomycin (Thermo 
Fisher Scientific) for 48 h in 96-well flat-bottom culture plates (Corning).  The cell 
proliferation was estimated by BrdU incorporation during the last 18 h of the 48-h 
culture.  Cell Proliferation Enzyme-linked Immunosorbent Assay (ELISA) BrdU 
(colorimetric) Kit (Roche Diagnostics) was used for measurement of BrdU 
incorporation following the manufacturer’s instructions. 
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2.2.4. Flow cytometoric analysis of cell cycle arrest and apoptosis 
6×105 splenocytes were cultured with 60 µg/ml PHA co-cultured with 30 mg/ml 
IVIg or human albumin for 48 h.  The cultured splenocytes were stained with 
allophycocyanin (APC)-labeled anti-CD3 antibody (eBioscince, Thermo Fisher 
Scientific), and co-stained with BrdU Flow Kit (BD Pharmingen, BD Biosciences) or 
fluorescein isothiocyanate (FITC)-conjugated Annexin V (BioLegend, San Diego, CA, 
USA) following manufacturer’s instruction.  The labeled splenocytes were analyzed by 
flow cytomerter gating on CD3+ T cells to estimate cell cycle distribution or fluorescent 
intensity of Annexin V.  FlowJo software (FlowJo, Ashland, OR, USA) was used for 
analysis of flow cytometoric data. 
 
2.2.5. Purification of T cells from murine splenocytes 
CD3+ T cells were purified by using Pan T cell Isolation Kit II (Miltenyi Biotec), 
and CD25- T cells were isolated from purified CD3+ T cells by using CD25 MicroBead 
Kit (Miltenyi Biotec).  Both kits were used following the manufacturer’s instructions. 
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2.2.6. T cell culture with phytohemagglutinin (PHA) or anti-CD3 antibody 
3×105 of purified CD3+ T cells or CD25- T cells were cultured with 1.25, 2.5, 5, 
10, or 20 μg/ml PHA, or 0.125, 0.25 0.5, 1 g/ml immobilized anti-CD3 antibody upon 
co-stimulation with 10 mg/ml IVIg or human albumin in 200 µl of culture medium.  
The cell proliferation was estimated by BrdU incorporation during the last 18 h of the 
48-h culture.  Cell Proliferation Enzyme-linked Immunosorbent Assay (ELISA) BrdU 
(colorimetric) Kit (Roche Diagnostics) was used for measurement of BrdU 
incorporation following the manufacturer’s instructions. 
 
2.2.7. Flow cytometoric analysis of regulatory T cells (Treg) 
1.2×106 of purified CD3+ T cells or CD25- T cells were cultured with 1 g/ml 
immobilized anti-CD3 antibody upon co-stimulation with 10 mg/ml IVIg or human 
albumin in 200 µl of culture medium.  After cultivation, the cells were stained with 
APC-labeled anti-CD3 antibody (eBioscince, Thermo Fisher Scientific), and treated by 
Foxp3/Transcription Factor Stain Buffer (eBioscince, Thermo Fisher Scientific) to 
co-stain with phycoerythrin (PE)-conjugated anti-Foxp3 antibody (eBioscince, Thermo 
Fisher Scientific).  The stained cells were analyzed by a flow cytomerter. 
FlowJo software was used for analysis of flow cytometoric data. 
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2.2.8. Analysis of cytokine production 
Production of interleukin (IL)-10 and IL-2 in supernatant of above T cell culture 
was estimated by using IL-10 Mouse Uncoated ELISA Kit (Thermo Fisher Scientific) 
or sandwich enzyme-linked immunosorbent assay using ELISA MAXTM Standard Set 
Mouse IL-2 (BioLegend).  These kits were used following the manufacturer’s 
instructions. 
 
2.2.9. IL-2 supplementation assay 
250 pg/ml recombinant IL-2 (BioLegend) was added to above T cell culture 
stimulated with 1 μg/ml anti-CD3 antibody and co-stimulated with 10 mg/ml IVIg for 
48 h.  After cultivation, the proliferations were estimated by proliferation assay.  The 
T cell proliferation was estimated by BrdU incorporation during the last 18 h of the 48-h 
culture.  Cell Proliferation Enzyme-linked Immunosorbent Assay (ELISA) BrdU 
(colorimetric) Kit (Roche Diagnostics) was used for measurement of BrdU 
incorporation following the manufacturer’s instructions. 
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2.2.10. Western blotting 
1×107 CD3+ T cells were cultured with 1 g/ml immobilized anti-CD3 antibody 
(BioLegend) supplemented with or without 10 mg/ml IVIg for 0, 0.5, 1, 3, 6 h.  The 
cultured T cells were washed with chilled PBS twice, and lysed with a lysis buffer [50 
mMTris-HCl/ 150 mM NaCl/ 1% Triton-X100/ 0.1% Sodium dodecyl sulfate (SDS), 
pH 7.5] supplemented with Complete Protease Inhibitor Cocktail (Roche Diagnostics), 
Aprotinin (Roche Diagnostics), Pefabloc SC (Roche Diagnostics), and Phosphatase 
Inhibitor Cocktail (Nacalai tesque, Kyoto, Japan) on ice for 30 min.  For the separation 
of nuclear and cytoplasmic proteins, cultured T cells were treated with NE-PERTM 
Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific) supplemented 
with Complete Protease Inhibitor Cocktail (Roche Diagnostics), Aprotinin (Roche 
Diagnostics), Pefabloc SC (Roche Diagnostics).  Whole cell lysates or separated 
nuclear proteins were separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) under reducing conditions.  Separated proteins were 
transferred onto a PVDF membrane (Merck Millipore LTd., Sigma-Aldrich).  The 
membrane was incubated with anti-IB, GAPDH, NFAT1, Lamin A/C, phospho-Erk1/2, 
Erk, phospho-ZAP-70 or ZAP-70 antibody respectively at 4˚C overnight and then 
horseradish peroxidase (HRP)-conjugated anti-rabbit IgG secondary antibody at 1h 
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room temperature.  Detection of positive signals was performed by ECL Prime 
Western Blotting Detection System (GE Healthcare Bio-Sciences, Tokyo, Japan). 
 
2.2.11. Immunoprecipitation 
Purified T cells were cultured with immobilized anti-CD3 antibody (1 µg/ml) 
supplemented with or without IVIg (10 mg/ml) for 0, 3, or 6 h.  After cultivation, T 
cells were harvested and washed twice with ice cold PBS.  Whole protein was 
extracted from the cultured cells using a lysis buffer [50 mMTris-HCl/ 150 mM NaCl/ 
1% Triton-X100/ 0.1% SDS, pH 7.5] supplemented with complete protease inhibitor 
cocktail (Roche Diagnostics), aprotinin (Roche Diagnostics), Pefabloc SC (Roche 
Diagnostics), and phosphatase inhibitor cocktail (Nacalai Tesque) on ice for 30 min.  
Tyrosine-phosphorylated proteins were immunoprecipitated using agarose-conjugated 
anti-phosphotyrosine antibody (Merck Millipore, Sigma-Aldrich) 
 
2.2.12. nano LC-MS/MS analysis 
     Fractionated protein bands in a SDS-PAGE gel (visualized by coomassie brilliant 
blue staining) were excised and digested using sequencing grade modified trypsin 
(Promega Corporation, WI).  Resultant peptide mixtures were analyzed by nano 
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LC-MS/MS using an Ultimate 3000 RSLCnano (Thermo Fisher Scientific) coupled to a 
LTQ Orbitrap XL (Thermo Fisher Scientific).  Identification of proteins was 
performed with Proteome Discoverer v2.2 (Thermo Fisher Scientific) and Mascot 
(Matrix Science Ltd, London, UK). 
 
2.2.13. Statistical analysis 
Data are represented as means ± SD.  Representative data are from three 
independent experiments.  A non-repeated analysis of variance (ANOVA) was applied 
to the comparisons of data among four groups; when a difference was significant, a post 
hoc analysis using the Turkey test was performed.  Statistical significance was defined 
as p < 0.05. 
  
36 
 
2.3. Results 
 
2.3.1. IVIg suppresses proliferation of splenocytes upon stimulation with T cell-tropic 
stimulants 
     To test T cell immunosuppressive capacity of IVIg, splemocytes stimulated with 
T cell-tropic stimulants (PHA and ConA) were cultured with IVIg.  IVIg suppressed 
proliferation of splenocytes stimulated with PHA or Con A (Fig. 7A and B), but not that 
stimulated with an activator of innate immunity (LPS, Fig. 7C).  These results suggest 
that IVIg preferentially suppress T cell activation. 
 
2.3.2. IVIg induces G1 cell cycle arrest of T cells, but does not induce apoptosis 
     To confirm whether IVIg induces G1 cell cycle arrest and/or apoptosis of T cells, 
I analyzed cell cycle distribution of splenocytes stimulated with PHA by flow 
cytometric analysis gated on CD3+ T cells.  IVIg co-stimulation increased percentage 
of CD3+ T cells in G1 phase (53.4% ± 1.53, Fig. 8A right and 8B) as compared with 
albumin (30.5% ± 1.37) and saline (32.6 ± 2.76).  By contrast, T cells in S phase were 
decreased by IVIg treatment (7.6% ± 1.30) as compared with albumin (35.5% ± 0.36) 
and saline (31.5% ± 1.21).  These results show that IVIg induces G1 cell cycle arrest of 
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T cells.  On the other hand, intensity of annexin V was comparable with T cells treated 
with IVIg, albumin and saline (Fig. 8C), showing that IVIg does not induce apoptosis of 
T cells. 
 
2.3.3. IVIg suppresses proliferation of purified T cells upon TCR ligation 
     To assess whether IVIg directly suppress T cell activation, I estimated 
immunosuppressive capacity of IVIg on purified T cells.  IVIg suppressed 
proliferation of purified T cells (Fig. 9B) upon stimulation with PHA, similar to the 
same manner seen in whole splenocytes (Fig. 9A).  I also assessed whether IVIg can 
suppress proliferation of T cells stimulated with anti-CD3 antibody (closer to 
physiological stimulation).  IVIg suppressed proliferation of splenocytes (Fig. 9D) and 
purified T cells (Fig. 9E) stimulated with anti-CD3 antibody.  These results indicate 
that IVIg acts directly on T cells and suppresses their activation upon TCR ligation.   
I next tested whether naturally-occurring Treg (nTreg) was involved in the above 
T cell regulatory activity.  The immunosuppressive activity of IVIg on T cells was still 
intact after depletion of CD25+ T cells (nTreg population) from purified T cells (Fig. 9C 
and F).  These results suggest that IVIg directly acts on non-Treg conventional T cells 
to suppress their activation. 
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2.3.4. IVIg does not induce expansion of CD4+ Foxp3+ Treg 
     Treg is classified into nTreg that develops in the thymus or inducible Treg (iTreg) 
that differentiate in the periphery.  In the previous section, I revealed that the T cell 
regulatory activity of IVIg was still intact in the absence of CD25+ nTreg (Fig. 9C and 
F), but the possibility still remained that IVIg co-stimulation could induce expansion of 
iTreg.  To test whether IVIg triggers expansion of iTreg, IVIg-treated purified T cells 
and CD25- T cells were analyzed by flow cytometoric analysis.  IVIg failed to expand 
CD4+ Foxp3+ Treg in purified T cells (Fig. 10A) as well as in CD25- T cells (Fig. 10B).  
Furthermore, I quantified production of IL-10, which behaves inhibitory cytokine and 
produced by Foxp3- Treg (Tr1 cells).  IVIg did not induce IL-10 production (Fig. 10D), 
suggesting that Tr1 cells were not inducted by IVIg treatment.  Taken together, these 
results show that IVIg does not have any impact on expansion of Treg as well as on 
production of IL-10. 
 
2.3.5. IVIg negatively regulates TCR signaling 
      The fact that IVIg suppressed proliferation of purified T cells stimulated with 
anti-CD3 antibody (Fig. 9E and F) without expansion of Treg (Fig. 10) suggests that 
IVIg can directly suppress TCR signaling.  To obtain stronger evidence that IVIg 
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suppress TCR signaling, I quantified IL-2 production induced by activation of TCR 
signaling.  IVIg co-stimulation inhibited IL-2 production from purified T cells upon 
stimulation with anti-CD3 antibody (Fig. 11A).  Furthermore, adding back of 
recombinant IL-2 to IVIg-treated T cells abrogated IVIg-driven regulatory activity of T 
cell proliferation (Fig. 11B).  These results indicate that IVIg perform its T cell 
regulatory activity by inhibition of TCR signaling. 
     Next, I tested whether IVIg actually inhibited TCR signaling.  TCR signaling 
branches out along three major pathways [the nuclear factor-B (NF-B), 
Ca2+-calcineurin-nuclear factor of activated T cells (NFAT), and mitogen-activated 
protein kinase (MAPK)-AP1 pathways], all of which are essential for full activation of 
T cells [57].  IVIg co-stimulation impaired degradation of IB, which inactivated 
NF-B transcription factor (Fig. 12A).  I also found that IVIg inhibited nuclear 
translocation of NFAT1 transcription factor (Fig. 12B) and phosphorylation of Erk1/2 
(MAPK) (Fig. 12C).  The fact that IVIg negatively regulates these three pathways 
suggests that IVIg affects TCR-membrane proximal event.  Thus, I next tested whether 
IVIg suppressed the activation of a TCR-membrane proximal kinase ZAP-70.  IVIg 
co-stimulation inhibited the phosphorylation of ZAP-70 (Fig. 13). 
     To deeper analyze signaling event that IVIg acts directly on T cells and 
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suppresses their activation, IVIg-treated T cell lysates were applied to 
immunoprecipitation using anti-phosphotyrosine antibody (4G10).  IVIg 
co-stimulation induced phosphorylation of 55 kDa protein (Fig. 14).  Futhermore, the 
immunoprecipitates contained tyrosine-phosphorylated proteins which were specifically 
increased by IVIg co-stimulation (Fig. 15).  Those proteins were observed at 55 kDa 
(Band 1) and 200 kDa (Band 2) by SDS-PAGE analysis.  Protein identification by 
nano LC-MS/MS showed that Band 1 and 2 contained a ZAP-70 modulator Lck kinase 
and a Lck modulator phosphatase CD45, respectively (Table 1 and 2). 
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2.4. Discussion 
 
     In this chapter, I revealed that IVIg acted directly on conventional T cells to 
suppress their activation upon TCR ligation.  It is widely accepted that IVIg acts on 
APC to indirectly suppress T cell activation [54,55,56].  The direct T cell regulatory 
activity of IVIg shown in this chapter is in marked contrast to those previous reports. 
     Furthermore, I also found that IVIg inhibited TCR signaling.  IVIg negatively 
regulated the three pathways that constitute TCR signaling (NF-B, 
Ca2+-calcineurin-NFAT, and MAPK-AP1 pathways), suggesting that IVIg affects the 
TCR-proximal signaling events to suppress T cell activation.  In fact, IVIg did not 
suppress T cell proliferation stimulation with PMA and ionomycin which bypass TCR 
ligation (data not shown).  In addition, IVIg co-stimulation inhibited the activation of 
TCR-proximal ZAP-70 kinase (Fig. 13).  Preliminary results of immunoprecipitation 
by using anti-phosphotyrosine antibody indicated that IVIg induced protein 
phosphorylation.  Those immunoprecipitated proteins contained Lck kinase, CD45 
tyrosine phosphatase.  Lck is an upstream kinase of ZAP-70 and has both activating 
(Y394) and inhibitory (Y505) phosphorylation sites.  CD45 positively and negatively 
regulates TCR signaling through dephosphorylation of Lck at Y394 and Y505 [58,59].  
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Recruitment of CD45 to immunological synapse leads to reset of TCR signaling [60,61].  
Besides, dedicator of cytokinesis 8 (DOCK8) was also identified by nano LC-MS/MS 
analysis of Band 2 (Table 2).  DOCK8 is a member of the DOCK family of proteins 
[62], and it has an essential role in immune synapse formation [63].  In addition, 
myosin-9 which is a protein identified by nano LC-MS/MS analysis of Band 2 (Table 2) 
is also required for maturation of the immunological synapse [64].  The fact that 
molecules associated with immunological synapse formation were identified from 
IVIg-treated immunoprecipitates (shown in Fig. 13, Band 1 and 2; Table 1 and 2) 
suggested that the immunosuppressive target of IVIg would be a component of immune 
synapse.  To analyze the role of these molecules on the T cell regulatory activity of 
IVIg is a vital task for the future. 
     In addition to the elucidation of the T cell suppression mechanism of IVIg, it is 
necessary to assess the pathophysiological importance of its immunosuppressive 
activity.  The T cell regulatory activity of IVIg discovered in this chapter is a direct 
action on conventional T cells.  Thus, to test whether IVIg suppresses T cell-driven 
pathologies such as allograft rejection or type 1 diabetes through its direct inhibition of 
T cell activation would be a suitable trial model.  
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Fig. 7 IVIg suppresses proliferation of T cells stimulated by T cell-tropic stimulants.  
A, B, C IVIg suppressed proliferation of splenocytes stimulated with PHA (A) and Con 
A (B), but not that of splenocytes stimulated with LPS (C).  Murine splenocytes were 
cultured with PHA, Con A or LPS and co-stimulated with IVIg (10 mg/ml), albumin 
(10 mg/ml), mitomycin C (50 g/ml), or saline.  Cell proliferation was measured by 
BrdU incorporation.  *Significantly different at p < 0.05 among saline, human albumin, 
IVIg, and mitomycin C by non-repeated ANOVA and the post hoc Tukey test.  Data 
are presented as means ± SD (n = 3). 
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Fig. 8 IVIg induces G1 cell cycle arrest of T cells, but not apoptosis.  A IVIg 
induced G1 cell cycle arrest of T cells.  Murine suplenocyts were cultured with PHA 
and co-stimulated with IVIg (10 mg/ml), albumin (10 mg/ml) or saline.  The cultured 
splenocytes were labeled with APC-conjugated anti-CD3 antibody, and co-stained with 
anti-BrdU antibody in BrdU Flow Kit.  CD3+ T cells were analyzed by a flow 
cytometer.  B Cell cycle distribution of CD3+ T cells cultured with saline, albumin, or 
IVIg.  Bars labeled a-c indicate statistically significant differences among the cell 
cycle distributions (p < 0.05 by non-repeated ANOVA with post hoc Tukey test).  Data 
are presented as means ± SD (n = 3).  C IVIg failed to induce apoptosis of T cells.  
Whole suplenocytes were cultured with PHA and co-stimulated with IVIg (10 mg/ml), 
albumin or saline.  The cultured cells were labeled with APC-conjugated anti-CD3 
antibody, and co-stained with FITC-conjugated Annexin V.  CD3+ T cells were 
analyzed by a flow cytometer. 
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Fig. 9 IVIg suppresses proliferation of purified T cells and CD25- T cells.  A, D 
IVIg suppressed proliferation of whole splenocytes upon stimulation with PHA (A) or 
anti-CD3 antibody (D).  Whole splenocytes were cultured with PHA and anti-CD3 
antibody and co-stimulated with IVIg (10 mg/ml), albumin (10 mg/ml), mitomycin C 
(50 g/ml), or saline.  Cell proliferation was measured by BrdU incorporation.  
*Significantly different at p < 0.05 among saline, albumin, IVIg, and mitomycin C by 
non-repeated ANOVA and the post hoc Tukey test.  Data are presented as means ± SD 
(n = 3). 
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Fig. 10 IVIg does not expand Treg.  A, B IVIg failed to expand Treg cells.  Purified 
T cells (A) or CD25- Tcells (B) were cultured with anti-CD3 antibody and co-stimulated 
with IVIg (10 mg/ml), albumin (10 mg/ml), or saline.  Cultured T cells were stained 
with APC-conjugated anti-CD4 antibody and incubated with Foxp3/Transcription 
Factor Stain Buffer to co-stain PE-conjugated anti-Foxp3 antibody.  Stained T cells 
were analyzed by a flow cytometer.  C Rate of CD4+ Foxp3+ Treg in cultured T cells.  
No significantly different at p > 0.05 among saline, albumin, IVIg, and mitomycin C by 
non-repeated ANOVA and the post hoc Tukey test.  Data are presented as means ± SD 
(n = 3).  D IVIg did not induce production of IL-10 from T cells. Purified T cells were 
cultured with anti-CD3 antibody and co-stimulated with IVIg (10 mg/ml), albumin (10 
mg/ml), or saline.  Produced IL-10 in the supernatant was quantified by ELISA.  No 
significantly different at p > 0.05 among saline, albumin, IVIg, and mitomycin C by 
non-repeated ANOVA and the post hoc Tukey test.  Data are presented as means ± SD 
(n = 3). 
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Fig. 11 IVIg suppresses IL-2 production from purified T cells, and its suppressive 
activity was canceled by adding of exogenous recombinant IL-2.  A IVIg 
suppressed IL-2 production from purified T cells.  Purified T cells were cultured with 
anti-CD3 antibody and co-stimulated with IVIg (10 mg/ml), albumin (10 mg/ml), 
mitomycin C (50 g/ml) or saline.  Produced IL-2 in the supernatant was quantified by 
ELISA.  B Exogenous recombinant IL-2 abrogated IVIg’s suppressive activity on T 
cell proliferation.  Recombinant IL-2 (250 pg/ml) was exogenously added to T cells 
stimulated with anti-CD3 antibody (2 g/ml) and IVIg (10 mg/ml).  Cell proliferation 
was measured by BrdU incorporation.  Bars labeled a-d indicate statistically 
significant differences among the cell cycle distributions (p < 0.05 by non-repeated 
ANOVA with post hoc Tukey test).  Data are presented as means ± SD (n = 3). 
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Fig. 12 IVIg negatively regulated TCR signaling.  A B C IVIg impaired IB 
degradation (A), translocation of NFAT1 (B), and phosphorylation of Erk (C). Purified 
T cells were cultured with anti-CD3 antibody and co-stimulated with or without IVIg 
for 0, 0.5, 1, 3, or 6 h.  Proteins from cultured T cells were fractionated by SDS-PAGE, 
and then transferred to PVDF membrane.  IB, GAPDH, NFAT1, Lamin A/C, 
p-Erk1/2, and Erk1/2 were detected by western blotting. 
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Fig. 13 IVIg inhibited the phosphorylation of a TCR-membrane proximal kinase 
ZAP-70.  Purified T cells were cultured with anti-CD3 antibody and co-stimulated 
with or without IVIg for 0, 3, or 6 h.  Proteins from cultured T cells were fractionated 
by SDS-PAGE, and then transferred to PVDF membrane.  ZAP-70 and pZAP-70 were 
detected by western blotting. 
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Fig. 14 IVIg co-stimulation induced tyrosine phosphorylation of 55 kDa proteins.  
Purified T cells were cultured with anti-CD3 antibody and co-stimulated with or 
without IVIg for 0, 3, or 6 h, and whole T cell lysates were applied to 
immunoprecipitation using anti-phosphotyrosine antibody.  Immunoprecipitates were 
fractionated by SDS-PAGE, and then transferred to PVDF membrane.  
Tyrosine-phosphorylated proteins were detected by western blotting using 
anti-phosphotyrosine antibody. 
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Fig. 15 IVIg-treated immunoprecipitates specifically contained 55 and 200 kDa 
proteins.  Purified T cells were cultured with anti-CD3 antibody and co-stimulated 
with or without IVIg for 0, 3, or 6 h, and whole T cell lysates were applied to 
immunoprecipitation using anti-phosphotyrosine antibody.  Immunoprecipitates were 
fractionated by SDS-PAGE, and visualized by coomassie brilliant blue staining. 
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General conclusions 
 
     IVIg therapy is a beneficial treatment for autoimmune and severe infectious 
disorders.  However, its immunosuppressive mechanisms remain unclear.  To 
elucidate the therapeutic mechanisms of IVIg would provide valuable drug targets on 
the treatment of chronic and acute inflammatory diseases, and the molecular targeted 
drugs that mimic the therapeutic effects of IVIg would be more effective and safer 
treatment for these diseases.  In this thesis, I aimed to redefine and elucidate the target 
cell subsets and immunosuppressive mechanisms of IVIg based on a hypothesis that 
IVIg fulfills its immunosuppressive activities through multiple cell targets and 
molecular mechanisms.   
     In this study, I discovered two novel immunosuppressive roles of IVIg.  First, I 
demonstrated that IVIg acted on steady-state B cells and suppressed their homeostatic 
expansion accompanied with B cell aggregation (chapter 1).  These B cell regulatory 
effects are novel activity of IVIg that have not been reported previously, and present 
results suggest that IVIg can suppress dysregulation of B cell homeostasis leading to 
chronic inflammation.  Dysregulation of B cell homeostasis provokes over production 
of autoantibodies, and autoimmune diseases characterized by production of multiple 
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autoantibodies is higher prevalence in women than man [46].  B cell activating factor 
(BAFF) and female sex hormones (e.x., estrogen and prolactin) contribute 
above-mentioned B cell-driven pathologies [39,40,41,48,49], and would be the 
responsible factors for homeostatic expansion of B cells.  To evaluate the participation 
of these molecules to homeostatic expansion of B cells would be provide insights into 
identification of the B cell regulatory mechanism by IVIg.  Second, I showed that IVIg 
acted directly on conventional T cells and suppressed their activation (chapter 2).  
Previous studies suggested that IVIg acted APC and then expanded Treg to suppress the 
activation of conventional T cells.  In contrast, present results indicated that IVIg could 
directly suppress the activation of conventional T cells.  These findings are in marked 
contrast to previous reports.  Furthermore, I also found that IVIg negatively regulated 
the three pathways that constitute TCR signaling (NF-B, Ca2+-calcineurin-NFAT, and 
MAPK-AP1 pathways), suggesting that IVIg suppressed TCR-membrane proximal 
signaling event.  In fact, I revealed that IVIg inhibited the activation of a 
TCR-membrane proximal kinase ZAP-70.  In my preliminary experiments, I showed 
that the immunoprecipitates that immunoprecipitated by anti-phosphotyrosine antibody 
contained a ZAP-70 modulator Lck kinase and a Lck modulator phosphatase CD45.  
To analyze the role of these molecules on the T cell regulatory activity of IVIg is an 
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intriguing trial for the future to fully understand immunosuppressive mechanism of IVIg.  
Taken together, these results indicate that IVIg acts on different immune cells 
depending on the immune activation state and fulfills its versatile immunosuppressive 
capacity by inhibition of the activation of target cells.  Autoimmune disorders have a 
variety of inflammatory conditions caused by versatile pathogenic immune cells.  The 
B and T cell regulatory activities of IVIg discovered in this thesis would provide 
valuable drug targets on the treatment of chronic and acute inflammatory disorders. 
     In recent years, the relationship between aging and inflammation has been 
elucidated [65].  Chronic inflammation is observed not only in rare intractable diseases, 
but also in age-related diseases such as type 2 diabetes, Alzheimer’s disease and 
neurodegenerative diseases [65].  To elucidate the versatile immunosuppressive 
mechanism of IVIg would be an important basic research in the development of 
treatments for age-related inflammatory diseases as well as intractable diseases.  In the 
future, Japan will become a super-aging society, and the development of treatments for 
age-related diseases is indispensable.  IVIg therapy, which is used only in limited 
treatment of intractable diseases, has the potential to provide immunosuppressive drug 
targets that contribute to the development of treatments for a wide range of 
inflammatory diseases.  
59 
 
Acknowledgments 
 
     This thesis study has been carried out at the Molecular Biochemistry Laboratory, 
Department of Molecular Biotechnology, Graduate School of Advanced Science of 
Matter, Hiroshima University. 
     I am deeply grateful to Prof. Seiji Kawamoto and Dr. Takashi Fujimura, who give 
me insightful comments and suggestions throughout this study.  I also want to thank 
Prof. Tsunehiro Aki and Prof. Akio Kuroda for their advice on my doctoral thesis.  
Meticulous comments of Dr. Miyako Nakano and Prof. Kazuhisa Ono (Emeritus 
Professor, Hiroshima University) were also an enormous help to me.  I thank Tomoko 
Amimoto (the Natural Science Center for Basic Research and Development, Hiroshima 
University) for her technical support on nano LC-MS/MS analysis.  I would like to 
offer my special thanks to my laboratory members, who give me warm encouragements 
and supports. 
     I am a recipient of a JSPS Research Fellowship for Young Scientists (DC2).  
This work was supported by JSPS KAKENHI Grant Number JP19J10257.  
Finally, I would like to express my gratitude to my family, who give me a chance 
to chase my dream. 
60 
 
References 
 
[1] A.F. Barahona Afonso, C.M. Joao, The Production Processes and Biological Effects 
of Intravenous Immunoglobulin, Biomolecules 6 (2016) 15. 
[2] A.W. Zuercher, R. Spirig, A. Baz Morelli, F. Kasermann, IVIG in autoimmune 
disease - Potential next generation biologics, Autoimmun Rev 15 (2016) 
781-785. 
[3] V.B. E., Untersuchungen ueber das Zustandekommen der Diphtherie-Immunitat bei 
Thieren (in Germany), Dtsch. Med. Wochenschr. 16 (1890) 1145-1148. 
[4] V.B. E., K. S., Ueber das Zustandekommen der Diphtherie-Immunitat und der 
Tetanus-Immunitat bei Thieren (in Germany), Dtsch. Med. Wochenschr. 16 
(1890) 1113-1114. 
[5] O.C. Bruton, Agammaglobulinemia, Pediatrics 9 (1952) 722-728. 
[6] P. Imbach, S. Barandun, C. Baumgartner, A. Hirt, F. Hofer, H.P. Wagner, High-dose 
intravenous gammaglobulin therapy of refractory, in particular idiopathic 
thrombocytopenia in childhood, Helv Paediatr Acta 36 (1981) 81-86. 
[7] L. Wang, F.S. Wang, M.E. Gershwin, Human autoimmune diseases: a 
comprehensive update, J Intern Med 278 (2015) 369-395. 
[8] M.R. Arbuckle, M.T. McClain, M.V. Rubertone, R.H. Scofield, G.J. Dennis, J.A. 
James, J.B. Harley, Development of autoantibodies before the clinical onset of 
systemic lupus erythematosus, N Engl J Med 349 (2003) 1526-1533. 
[9] R. Jonsson, E. Theander, B. Sjostrom, K. Brokstad, G. Henriksson, Autoantibodies 
present before symptom onset in primary Sjogren syndrome, Jama 310 (2013) 
1854-1855. 
[10] M.M. Nielen, D. van Schaardenburg, H.W. Reesink, R.J. van de Stadt, I.E. van der 
61 
 
Horst-Bruinsma, M.H. de Koning, M.R. Habibuw, J.P. Vandenbroucke, B.A. 
Dijkmans, Specific autoantibodies precede the symptoms of rheumatoid 
arthritis: a study of serial measurements in blood donors, Arthritis Rheum 50 
(2004) 380-386. 
[11] S. Kotake, N. Udagawa, N. Takahashi, K. Matsuzaki, K. Itoh, S. Ishiyama, S. Saito, 
K. Inoue, N. Kamatani, M.T. Gillespie, T.J. Martin, T. Suda, IL-17 in synovial 
fluids from patients with rheumatoid arthritis is a potent stimulator of 
osteoclastogenesis, J Clin Invest 103 (1999) 1345-1352. 
[12] D. Li, B. Guo, H. Wu, L. Tan, C. Chang, Q. Lu, Interleukin-17 in systemic lupus 
erythematosus: A comprehensive review, Autoimmunity 48 (2015) 353-361. 
[13] L.W. Zhang, P.R. Zhou, P. Wei, X. Cong, L.L. Wu, H. Hua, Expression of 
interleukin-17 in primary Sjogren's syndrome and the correlation with disease 
severity: A systematic review and meta-analysis, Scand J Immunol 87 (2018) 
e12649. 
[14] A. Waisman, J. Hauptmann, T. Regen, The role of IL-17 in CNS diseases, Acta 
Neuropathol 129 (2015) 625-637. 
[15] L.S. Walker, M. von Herrath, CD4 T cell differentiation in type 1 diabetes, Clin 
Exp Immunol 183 (2016) 16-29. 
[16] H. Kita, Z.X. Lian, J. Van de Water, X.S. He, S. Matsumura, M. Kaplan, V. 
Luketic, R.L. Coppel, A.A. Ansari, M.E. Gershwin, Identification of 
HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary 
cirrhosis: T cell activation is augmented by immune complexes cross-presented 
by dendritic cells, J Exp Med 195 (2002) 113-123. 
[17] C. Scheinecker, M. Bonelli, J.S. Smolen, Pathogenetic aspects of systemic lupus 
erythematosus with an emphasis on regulatory T cells, J Autoimmun 35 (2010) 
269-275. 
[18] K.M. Danikowski, S. Jayaraman, B.S. Prabhakar, Regulatory T cells in multiple 
sclerosis and myasthenia gravis, J Neuroinflammation 14 (2017) 117. 
62 
 
[19] F.A. Cooles, J.D. Isaacs, A.E. Anderson, Treg cells in rheumatoid arthritis: an 
update, Curr Rheumatol Rep 15 (2013) 352. 
[20] J.W. Newburger, M. Takahashi, J.C. Burns, Kawasaki Disease, J Am Coll Cardiol 
67 (2016) 1738-1749. 
[21] J.W. Newburger, Kawasaki disease: Medical therapies, Congenit Heart Dis 12 
(2017) 641-643. 
[22] G. Zandman-Goddard, Y. Levy, Y. Shoenfeld, Intravenous immunoglobulin 
therapy and systemic lupus erythematosus, Clin Rev Allergy Immunol 29 (2005) 
219-228. 
[23] R. Sakthiswary, D. D'Cruz, Intravenous immunoglobulin in the therapeutic 
armamentarium of systemic lupus erythematosus: a systematic review and 
meta-analysis, Medicine (Baltimore) 93 (2014) e86. 
[24] J. Jellusova, L. Nitschke, Regulation of B cell functions by the sialic acid-binding 
receptors siglec-G and CD22, Front Immunol 2 (2011) 96. 
[25] J.F. Seite, D. Cornec, Y. Renaudineau, P. Youinou, R.A. Mageed, S. Hillion, IVIg 
modulates BCR signaling through CD22 and promotes apoptosis in mature 
human B lymphocytes, Blood 116 (2010) 1698-1704. 
[26] T. Muta, T. Kurosaki, Z. Misulovin, M. Sanchez, M.C. Nussenzweig, J.V. Ravetch, 
A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates 
B-cell receptor signalling, Nature 368 (1994) 70-73. 
[27] M. Ballow, The IgG molecule as a biological immune response modifier: 
mechanisms of action of intravenous immune serum globulin in autoimmune 
and inflammatory disorders, J Allergy Clin Immunol 127 (2011) 315-323. 
[28] M.D. Kazatchkine, S.V. Kaveri, Immunomodulation of autoimmune and 
inflammatory diseases with intravenous immune globulin, N Engl J Med 345 
(2001) 747-755. 
63 
 
[29] A. Kessel, R. Peri, T. Haj, A. Snir, G. Slobodin, E. Sabo, I. Rosner, Y. Shoenfeld, 
E. Toubi, IVIg attenuates TLR-9 activation in B cells from SLE patients, J Clin 
Immunol 31 (2011) 30-38. 
[30] J.F. Seite, T. Guerrier, D. Cornec, C. Jamin, P. Youinou, S. Hillion, TLR9 
responses of B cells are repressed by intravenous immunoglobulin through the 
recruitment of phosphatase, J Autoimmun 37 (2011) 190-197. 
[31] V.K. Kuchroo, P.S. Ohashi, R.B. Sartor, C.G. Vinuesa, Dysregulation of immune 
homeostasis in autoimmune diseases, Nat Med 18 (2012) 42-47. 
[32] S.J. Kim, J.H. Won, B cell homeostasis and the development of chronic 
graft-versus-host disease: implications for B cell-depleting therapy, Leuk 
Lymphoma 53 (2012) 19-25. 
[33] M. Wunsch, C. Hohmann, B. Milles, C. Rostermund, P.V. Lehmann, M. Schroeter, 
A. Bayas, J. Ulzheimer, M. Maurer, S. Ergun, S. Kuerten, The Correlation 
between the Virus- and Brain Antigen-Specific B Cell Response in the Blood of 
Patients with Multiple Sclerosis, Viruses 8 (2016) 105. 
[34] A. Pollreisz, A. Assinger, S. Hacker, K. Hoetzenecker, W. Schmid, G. Lang, M. 
Wolfsberger, B. Steinlechner, E. Bielek, E. Lalla, W. Klepetko, I. Volf, H.J. 
Ankersmit, Intravenous immunoglobulins induce CD32-mediated platelet 
aggregation in vitro, Br J Dermatol 159 (2008) 578-584. 
[35] Y. Kaneko, F. Nimmerjahn, J.V. Ravetch, Anti-inflammatory activity of 
immunoglobulin G resulting from Fc sialylation, Science 313 (2006) 670-673. 
[36] M. Mitrevski, R. Marrapodi, A. Camponeschi, F.M. Cavaliere, C. Lazzeri, L. Todi, 
M. Visentini, Intravenous Immunoglobulin and Immunomodulation of B-Cell - 
in vitro and in vivo Effects, Front Immunol 6 (2015) 4. 
[37] P. Bjorck, S. Paulie, B. Axelsson, Interleukin-4-mediated aggregation of 
anti-IgM-stimulated human B cells: inhibition of aggregation but enhancement 
of proliferation by antibodies to LFA-1, Immunology 75 (1992) 122-128. 
64 
 
[38] C. Bossen, A. Tardivel, L. Willen, C.A. Fletcher, M. Perroud, F. Beermann, A.G. 
Rolink, M.L. Scott, F. Mackay, P. Schneider, Mutation of the BAFF furin 
cleavage site impairs B-cell homeostasis and antibody responses, Eur J Immunol 
41 (2011) 787-797. 
[39] V.T. Chu, P. Enghard, S. Schurer, G. Steinhauser, B. Rudolph, G. Riemekasten, C. 
Berek, Systemic activation of the immune system induces aberrant BAFF and 
APRIL expression in B cells in patients with systemic lupus erythematosus, 
Arthritis Rheum 60 (2009) 2083-2093. 
[40] E. Zollars, J. Bienkowska, J. Czerkowicz, N. Allaire, A.M. Ranger, L. Magder, M. 
Petri, BAFF (B cell activating factor) transcript level in peripheral blood of 
patients with SLE is associated with same-day disease activity as well as global 
activity over the next year, Lupus Sci Med 2 (2015) e000063. 
[41] X. Mariette, S. Roux, J. Zhang, D. Bengoufa, F. Lavie, T. Zhou, R. Kimberly, The 
level of BLyS (BAFF) correlates with the titre of autoantibodies in human 
Sjogren's syndrome, Ann Rheum Dis 62 (2003) 168-171. 
[42] E. Claudio, K. Brown, S. Park, H. Wang, U. Siebenlist, BAFF-induced 
NEMO-independent processing of NF-kappa B2 in maturing B cells, Nat 
Immunol 3 (2002) 958-965. 
[43] N. Kayagaki, M. Yan, D. Seshasayee, H. Wang, W. Lee, D.M. French, I.S. Grewal, 
A.G. Cochran, N.C. Gordon, J. Yin, M.A. Starovasnik, V.M. Dixit, BAFF/BLyS 
receptor 3 binds the B cell survival factor BAFF ligand through a discrete 
surface loop and promotes processing of NF-kappaB2, Immunity 17 (2002) 
515-524. 
[44] J. Jellusova, A.V. Miletic, M.H. Cato, W.W. Lin, Y. Hu, G.A. Bishop, M.J. 
Shlomchik, R.C. Rickert, Context-specific BAFF-R signaling by the NF-kappaB 
and PI3K pathways, Cell Rep 5 (2013) 1022-1035. 
[45] G. Recalde, T. Moreno-Sosa, F. Yudica, C.A. Quintero, M.B. Sanchez, G.A. Jahn, 
A.M. Kalergis, J.P. Mackern-Oberti, Contribution of sex steroids and prolactin 
to the modulation of T and B cells during autoimmunity, Autoimmun Rev 17 
65 
 
(2018) 504-512. 
[46] E. Ortona, M. Pierdominici, A. Maselli, C. Veroni, F. Aloisi, Y. Shoenfeld, 
Sex-based differences in autoimmune diseases, Ann Ist Super Sanita 52 (2016) 
205-212. 
[47] N. Kanda, K. Tamaki, Estrogen enhances immunoglobulin production by human 
PBMCs, J Allergy Clin Immunol 103 (1999) 282-288. 
[48] J. Correale, M.F. Farez, M.C. Ysrraelit, Role of prolactin in B cell regulation in 
multiple sclerosis, J Neuroimmunol 269 (2014) 76-86. 
[49] M. Dardenne, P.A. Kelly, J.F. Bach, W. Savino, Identification and functional 
activity of prolactin receptors in thymic epithelial cells, Proc Natl Acad Sci U S 
A 88 (1991) 9700-9704. 
[50] P. Ascenzi, A. Bocedi, M. Marino, Structure-function relationship of estrogen 
receptor alpha and beta: impact on human health, Mol Aspects Med 27 (2006) 
299-402. 
[51] C. Bole-Feysot, V. Goffin, M. Edery, N. Binart, P.A. Kelly, Prolactin (PRL) and its 
receptor: actions, signal transduction pathways and phenotypes observed in PRL 
receptor knockout mice, Endocr Rev 19 (1998) 225-268. 
[52] V. Goffin, N. Binart, P. Clement-Lacroix, B. Bouchard, C. Bole-Feysot, M. Edery, 
B.K. Lucas, P. Touraine, A. Pezet, R. Maaskant, C. Pichard, C. Helloco, N. 
Baran, H. Favre, S. Bernichtein, A. Allamando, C. Ormandy, P.A. Kelly, From 
the molecular biology of prolactin and its receptor to the lessons learned from 
knockout mice models, Genet Anal 15 (1999) 189-201. 
[53] D. Xiong, Y. Du, H.B. Wang, B. Zhao, H. Zhang, Y. Li, L.J. Hu, J.Y. Cao, Q. 
Zhong, W.L. Liu, M.Z. Li, X.F. Zhu, S.W. Tsao, L.M. Hutt-Fletcher, E. Song, 
Y.X. Zeng, E. Kieff, M.S. Zeng, Nonmuscle myosin heavy chain IIA mediates 
Epstein-Barr virus infection of nasopharyngeal epithelial cells, Proc Natl Acad 
Sci U S A 112 (2015) 11036-11041. 
66 
 
[54] A.S. De Groot, L. Moise, J.A. McMurry, E. Wambre, L. Van Overtvelt, P. 
Moingeon, D.W. Scott, W. Martin, Activation of natural regulatory T cells by 
IgG Fc-derived peptide "Tregitopes", Blood 112 (2008) 3303-3311. 
[55] B.M. Fiebiger, J. Maamary, A. Pincetic, J.V. Ravetch, Protection in antibody- and 
T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type 
II FcRs, Proc Natl Acad Sci U S A 112 (2015) E2385-2394. 
[56] J. Trinath, P. Hegde, M. Sharma, M.S. Maddur, M. Rabin, J.M. Vallat, L. Magy, 
K.N. Balaji, S.V. Kaveri, J. Bayry, Intravenous immunoglobulin expands 
regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin 
E2 in human dendritic cells, Blood 122 (2013) 1419-1427. 
[57] R.J. Brownlie, R. Zamoyska, T cell receptor signalling networks: branched, 
diversified and bounded, Nat Rev Immunol 13 (2013) 257-269. 
[58] M.L. Thomas, E.J. Brown, Positive and negative regulation of Src-family 
membrane kinases by CD45, Immunol Today 20 (1999) 406-411. 
[59] U. D'Oro, J.D. Ashwell, Cutting edge: the CD45 tyrosine phosphatase is an 
inhibitor of Lck activity in thymocytes, J Immunol 162 (1999) 1879-1883. 
[60] B.A. Freiberg, H. Kupfer, W. Maslanik, J. Delli, J. Kappler, D.M. Zaller, A. 
Kupfer, Staging and resetting T cell activation in SMACs, Nat Immunol 3 
(2002) 911-917. 
[61] R. Varma, G. Campi, T. Yokosuka, T. Saito, M.L. Dustin, T cell receptor-proximal 
signals are sustained in peripheral microclusters and terminated in the central 
supramolecular activation cluster, Immunity 25 (2006) 117-127. 
[62] J.F. Cote, K. Vuori, Identification of an evolutionarily conserved superfamily of 
DOCK180-related proteins with guanine nucleotide exchange activity, J Cell Sci 
115 (2002) 4901-4913. 
[63] C.J. Kearney, K.L. Randall, J. Oliaro, DOCK8 regulates signal transduction events 
to control immunity, Cell Mol Immunol 14 (2017) 406-411. 
67 
 
[64] S. Kumari, S. Vardhana, M. Cammer, S. Curado, L. Santos, M.P. Sheetz, M.L. 
Dustin, T Lymphocyte Myosin IIA is Required for Maturation of the 
Immunological Synapse, Front Immunol 3 (2012) 230. 
[65] S. Xia, X. Zhang, S. Zheng, R. Khanabdali, B. Kalionis, J. Wu, W. Wan, X. Tai, 
An Update on Inflamm-Aging: Mechanisms, Prevention, and Treatment,  2016 
(2016) 8426874. 
 
  
  
 
 
 
 
 
 
公表論文 
 
 
(1) Anti-inflammatory intravenous immunoglobulin (IVIg) suppresses homeostatic 
proliferation of B cells 
Ayane Hori, Takashi Fujimura, and Seiji Kawamoto 
Cytotechnology, 70, 921-927 (2018). 
 
 
(2) Intravenous immunoglobulin (IVIg) acts directly on conventional T cells to 
suppress T cell receptor signaling 
Ayane Hori, Takashi Fujimura, Mai Murakami, Jungyeon Park, and Seiji 
Kawamoto 
Biochemical and Biophysical Research Communications, 522, 792-798 (2020). 
 
 
  
  
 
 
 
 
 
 
参考論文 
 
 
(1) Intake of a fermented plant product attenuates allergic symptoms without changing 
systemic immune responses in a mouse model of Japanese cedar pollinosis. 
Takashi Fujimura, Ayane Hori, Hideto Torii, Shinsuke Kishida, Yoshinori 
Matsuura, and Seiji Kawamoto 
World Allergy Organization Journal, 11, 31-39 (2018). 
 
 
